Killer Cells: An Offensive Defense

When scientists realized that the immune system could discriminate self from non-self, they began to study whether the body could recognize tumor cells as foreign and then eliminate them. An immune response against foreign antigens (for example, viruses or bacteria) typically requires immunization and also that the foreign antigen binds to the body's own major-histocompatibiity [MHC] antigens (for example, HLA or H-2). Using in vitro assays to measure the killing of tumor cells, researchers

Written byLewis Lanier
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

When scientists realized that the immune system could discriminate self from non-self, they began to study whether the body could recognize tumor cells as foreign and then eliminate them. An immune response against foreign antigens (for example, viruses or bacteria) typically requires immunization and also that the foreign antigen binds to the body's own major-histocompatibiity [MHC] antigens (for example, HLA or H-2).

Using in vitro assays to measure the killing of tumor cells, researchers found that certain lymphocytes (a type of white blood cell responsible for recognizing foreign antigens) could lyse, or destroy, tumor cell targets. Surprisingly, these unique lymphocytes are present in the blood of normal, unimmunized individuals and they are able to recognize tumor cells that do not carry self MHC markers. The lack of requirement for immunization, and the ability to recognize tumor cells without MHC antigens, provided a working definition for a new type of cytotoxic, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies